Literature DB >> 29848176

The second and third amino acids of Pam2 lipopeptides are key for the proliferation of cytotoxic T cells.

Yohei Takeda1, Masahiro Azuma1, Ryoko Hatsugai1, Yukari Fujimoto2,3, Masahito Hashimoto4, Koichi Fukase3, Misako Matsumoto1, Tsukasa Seya1.   

Abstract

The TLR2 agonist, dipalmitoyl lipopeptide (Pam2LP), has been used as an immune adjuvant without much success. Pam2LP is recognised by TLR2/6 receptors in humans and in mice. This study examined the proliferative activity of cytotoxic T lymphocytes (CTL) using mouse Ag-presenting dendritic cells (DCs) and OT-I assay system, where a library of synthetic Pam2LP was utilised from the Staphylococcus aureus database. Ag-specific CTL expansion and IFN-γ levels largely depended on the Pam2LP peptide sequence. The first Aa is cysteine (Cys), which has an active SH residue to bridge fatty acids, and the second and third Aa are hydrophilic or non-polar. The sequence structurally adapted to the residual constitution of the reported TLR2/6 pocket. The inactive sequence contained proline or leucine/isoleucine after the first Cys. Notably, no direct activation of OT-I cells was detected without DCs by stimulation with the active Pam2LP having the Cys-Ser sequence. MyD88, but not TICAM-1 or IFN pathways, in DCs participates in DC maturation characterised by upregulation of CD40, CD80 and CD86. Hence, the active Pam2LPs appear suitable for dimeric TLR2/6 on DCs, resulting in induction of DC maturation.

Entities:  

Keywords:  CTL proliferation; MyD88-mediated dendritic cell priming; Pam2 lipopeptide; TLR2 agonist

Mesh:

Substances:

Year:  2018        PMID: 29848176      PMCID: PMC6830919          DOI: 10.1177/1753425918777598

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  50 in total

1.  Cutting edge: TLR2 directly triggers Th1 effector functions.

Authors:  Takayuki Imanishi; Hiromitsu Hara; Shinobu Suzuki; Nobutaka Suzuki; Shizuo Akira; Takashi Saito
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

2.  Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.

Authors:  Misako Matsumoto; Megumi Tatematsu; Fumiko Nishikawa; Masahiro Azuma; Noriko Ishii; Akiko Morii-Sakai; Hiroaki Shime; Tsukasa Seya
Journal:  Nat Commun       Date:  2015-02-18       Impact factor: 14.919

Review 3.  Cross-presentation by dendritic cells.

Authors:  Olivier P Joffre; Elodie Segura; Ariel Savina; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

Review 4.  A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2.

Authors:  Tsukasa Seya; Misako Matsumoto
Journal:  Int J Biochem Cell Biol       Date:  2002-08       Impact factor: 5.085

5.  A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling.

Authors:  Nadra J Nilsen; Gregory I Vladimer; Jørgen Stenvik; M Pontus A Orning; Maria V Zeid-Kilani; Marit Bugge; Bjarte Bergstroem; Joseph Conlon; Harald Husebye; Amy G Hise; Katherine A Fitzgerald; Terje Espevik; Egil Lien
Journal:  J Biol Chem       Date:  2014-12-11       Impact factor: 5.157

6.  Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.

Authors:  Nicole Asprodites; Liqin Zheng; Degui Geng; Cruz Velasco-Gonzalez; Luis Sanchez-Perez; Eduardo Davila
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

7.  Differential posttranslational processing confers intraspecies variation of a major surface lipoprotein and a macrophage-activating lipopeptide of Mycoplasma fermentans.

Authors:  M J Calcutt; M F Kim; A B Karpas; P F Mühlradt; K S Wise
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

8.  A database of bacterial lipoproteins (DOLOP) with functional assignments to predicted lipoproteins.

Authors:  M Madan Babu; M Leena Priya; A Tamil Selvan; Martin Madera; Julian Gough; L Aravind; K Sankaran
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

9.  TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo.

Authors:  Sayuri Yamazaki; Kohei Okada; Akira Maruyama; Misako Matsumoto; Hideo Yagita; Tsukasa Seya
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

Review 10.  Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.

Authors:  Tsukasa Seya; Hiroaki Shime; Yohei Takeda; Megumi Tatematsu; Ken Takashima; Misako Matsumoto
Journal:  Cancer Sci       Date:  2015-11-18       Impact factor: 6.716

View more
  3 in total

1.  Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.

Authors:  Arshpreet Kaur; Sakshi Piplani; Deepender Kaushik; Johnson Fung; Isaac G Sakala; Yoshikazu Honda-Okubo; Surinder K Mehta; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2022-04-20

2.  Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy.

Authors:  Sumito Yoshida; Hiroaki Shime; Misako Matsumoto; Masanori Kasahara; Tsukasa Seya
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

3.  The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions.

Authors:  Iván Parra-Izquierdo; Hari Hara Sudhan Lakshmanan; Alexander R Melrose; Jiaqing Pang; Tony J Zheng; Kelley R Jordan; Stéphanie E Reitsma; Owen J T McCarty; Joseph E Aslan
Journal:  Front Immunol       Date:  2021-08-30       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.